AAMS Internal Medicine & Therapeutics · Vol. 7 · Issue 3 · 2026-03-01
GLP-1 Receptor Agonists for Non-Alcoholic Steatohepatitis: A Phase III Trial
Laurent P, Yoshida K, Nwosu OC
Hôpital Beaujon, Clichy, France; Kyushu University Hospital, Fukuoka, Japan; University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Abstract
Double-blind phase III trial evaluating the efficacy and safety of semaglutide in 1,200 patients with biopsy-confirmed NASH and significant liver fibrosis.
Keywords: GLP-1 receptor agonist, NASH, liver fibrosis, phase III trial
Full Text
Double-blind phase III trial evaluating the efficacy and safety of semaglutide in 1,200 patients with biopsy-confirmed NASH and significant liver fibrosis.
This article is published open access by AAMS Internal Medicine & Therapeutics. The complete peer-reviewed text can be read on the journal page.
Author Citation Metrics
Metrics are sourced from public bibliometric records (OpenAlex) and each author's Google Scholar profile.